Month: June 2014

Is EGFR Mutation Testing Worth It In Non-Small Cell Lung Cancer?

Chiang Mai, Thailand – Lung cancer is a major cause of cancer death in Thailand. Epidermal Growth Factor Receptor (EGFR) inhibitors have been commonly used for the treatment of Non-Small Cell Lung Cancer (NSCLC), however, the drug costs are extremely high compared

Posted in Value in Health Regional Issues Tagged with: , , ,

Is CTC Implementation Cost-Effective for Colorectal Cancer?

Tokyo, Japan – Though the incidence and mortality of colorectal cancer can be reduced by regularly screening uptake, the current screening program, fecal occult blood test (FOBT) followed by optical colonoscopy (OC), does not work well due to low uptake rate

Posted in Value in Health Regional Issues Tagged with: , , ,

Inconsistency Among Utility Values in Japanese Studies –Are All QALYs Created Equal?

Tochigi, Japan – To conduct cost–utility analyses (CUAs) for pharmaceuticals, substantial data are required. One part of these data contains the utility values used when calculating the quality-adjusted life year (QALY). Using utility data in clinical trials in Japan was uncommon;

Posted in Value in Health Regional Issues Tagged with: , , ,

Cost-Utility Analysis Of Erythropoietin For Hemodialysis Patients

Bangkok, Thailand – Most patients receiving hemodialysis (HD) for end-stage renal disease (ESRD) currently receive erythropoietin (EPO) for anemia treatment. The goal of therapy is to achieve specific hemoglobin (Hb) target levels. Higher doses of EPO are used to attain higher

Posted in Value in Health Regional Issues Tagged with: , , , ,

Is It Time to Introduce Pneumococcal Vaccine to the National Immunization Programme in Malaysia?

Kuala Lumpur, Malaysia – Globally, Streptococcus pneumoniae (S. pneumoniae) has already been established as one of the leading causes of death among children under five years old. Since S. pneumoniae is a vaccine preventable disease, many countries have begun to address

Posted in Value in Health Regional Issues Tagged with: , ,

Pharmacoeconomics And Outcomes Research Is Evolving In Asia

Wallingford, CT, USA & Songkhla, Thailand – Recently, governments in the Asian region have tried their best to provide affordable health care in spite of economic dynamics. With the increasing pressure of constrained resources and more innovative medicines coming to the

Posted in Value in Health Regional Issues Tagged with: , , ,

Pharmacoeconomics in China: Where We Are And Where Are We Going?

Austin, TX, USA & Beijing, China – Since the implementation of health care reforms in 2009, the Chinese government has taken steps to improve the accessibility and affordability of health care services in China.

Posted in Value in Health Regional Issues Tagged with:

Collaboration Between Regulators And HTA Organizations To Improve Health Care Decision Making

PRINCETON, NJ, June 25, 2014 (ISPOR) — As announced today by the European network for Health Technology Assessment (EUnetHTA) and European Medicines Agency (EMA), Value in Health, the official journal for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), was pleased to publish

Posted in ISPOR News & Press, Value in Health Tagged with: , , ,

Potential Common Benchmark For Assessing New Diabetes Treatments

Basel, Switzerland – Many new products for type 2 diabetes mellitus (T2DM) will be launched in the coming years as a response to this ever-increasing world epidemic. Health technology assessment (HTA) agencies require cost-effectiveness studies of these agents, but no consistent

Posted in Systematic Reviews, Value in Health Tagged with: , , , ,